Literature DB >> 9133449

Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method.

P Keohavong1, D Zhu, A C Melacrinos, M A DeMichele, R J Weyant, J D Luketich, J R Testa, M Fedder, J M Siegfried.   

Abstract

Mutations in the K-ras gene are often identified in lung tumors and are implicated in the development of lung cancer. We used a sensitive method to analyze low-fraction mutations occurring in codon 12 of the K-ras gene in 114 primary lung tumors, including 77 adenocarcinomas, 31 squamous cell carcinomas and 6 adenosquamous carcinomas, which had previously been shown to be negative for codon 12 K-ras mutation in a first screening using less sensitive methods. Sixteen of these tumors were found to contain a low-fraction mutation, including 9 mutations among the adenocarcinomas, six mutations among the squamous cell carcinomas and one mutation among the adenosquamous carcinomas. Our study also showed that the occurrence of low-fraction mutation was associated with a positive smoking history, as was previously found for the occurrence of high-fraction mutation. Patients with low-fraction mutations were younger (mean age 58.8 years) than those with either high-fraction mutations (63.2 years) or no mutation (66 years). Patients with low-fraction mutations were more often stage 1 (8 of 10) than patients with either high fraction mutations (22 of 44) or no mutation (33 of 71). Moreover, the overall survival was better for the group with a low-fraction mutation than both the high-fraction mutation group and the group with no K-ras mutation, but due to small sample size, the difference was not statistically significant. Our results suggest that using highly sensitive methods of K-ras mutant detection in tumor DNA could obscure differences between patients in whom the mutation is found throughout the tumor, those in whom the mutation is only present in a small subpopulation and those who have no mutation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9133449     DOI: 10.1002/(sici)1097-0215(19970422)74:2<162::aid-ijc4>3.0.co;2-x

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

Review 1.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.

Authors:  C Mascaux; N Iannino; B Martin; M Paesmans; T Berghmans; M Dusart; A Haller; P Lothaire; A-P Meert; S Noel; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

2.  Topographic analysis of K- ras mutations in histologically normal lung tissues and tumours of lung cancer patients.

Authors:  P Keohavong; H H Mady; W M Gao; J M Siegfried; J D Luketich; M F Melhem
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.